Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...

What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and...

Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...

As the European biosimilars market surges, what do payers see as the next steps? The approval in 2018 of biosimilar versions of adalimumab (Abbvie's Humira) and trastuzumab (Roche's Herceptin) is a major boost to the...

How well does your MSL KOL engagement activity compare to competitors? What tools are being used today to measure engagement with KOLs? How often are KOLs surveyed regarding satisfaction levels? Which metrics are...

Can pharma persuade payers of the benefits of indication-level pricing? Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good...

Payers have great expectations for real world data. Is pharma meeting them? It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened...

Drug compounding meets unmet clinical needs, widens therapy choice and expands patient access to medicines. What are the lessons and opportunities for pharma? Drug compounding is a fast growing sector meeting the needs...